RecruitingNCT05250037

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)


Sponsor

Fred Hutchinson Cancer Center

Enrollment

250 participants

Start Date

Mar 30, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This observational trial studies whether respiratory viruses are the cause of lung disease (bronchiolitis obliterans syndrome \[BOS\] or graft-versus-host disease of the lung) and changes in lung function in patients who have received a donor stem cell transplant. Patients with chronic graft-versus-host disease (cGVHD) are at higher risk of developing BOS. Studies have also shown that patients who had a respiratory viral illness early after their transplant are at higher risk of developing lung problems later on. Patients who are at risk and who already have BOS might benefit from being monitored more closely. Spirometry is a way of assessing a patient's lung function and is often used to diagnose lung disease. Spirometry measured at home with a simple handheld device may reduce the burden of performing pulmonary function testing at a facility and potentially help patients get their lung disease diagnosed and treated sooner.


Eligibility

Min Age: 8 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking whether common respiratory viruses (like colds, flu, or RSV) trigger or worsen a serious lung complication called bronchiolitis obliterans syndrome (BOS) in people who have had an allogeneic stem cell transplant (a transplant from a donor). BOS causes permanent scarring in the small airways and is difficult to treat once it develops. **You may be eligible if...** - You are 8 years or older - You have received an allogeneic (donor) stem cell transplant for any reason - You have or recently developed chronic graft-versus-host disease (cGVHD), a complication where donor cells attack your body - You have had a recent decline in lung function or a recent respiratory infection **You may NOT be eligible if...** - You have already lost follow-up before the second evaluation - Your medical condition makes participation unsafe or impractical Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHome spirometry

Undergo spirometry measurements

PROCEDUREBiospecimen Collection

Undergo nasal and/or oral swabs, and blood collection

OTHERQuestionnaire Administration

Complete questionnaires


Locations(4)

Stanford Cancer Institute

Palo Alto, California, United States

University of Michigan Cancer Center

Ann Arbor, Michigan, United States

MD Anderson Cancer Center

Houston, Texas, United States

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05250037


Related Trials